Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 14/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.39 |
| ▸ | RBP4 | P02753 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6466324 | 0.85 | CTSS (0.38) | EPHX2CYP2C9RBP4CTSSCTSL | |
| SCHEMBL6464521 | 0.81 | CTSS (0.38) | EPHX2CYP2C9RBP4CTSSCTSL | |
| SCHEMBL6062899 | 0.76 | FAAH (0.37) | CYP2C9CTSSALDH1A1 | |
| SCHEMBL6061805 | 0.75 | RAB9A (0.32) | CTSS | |
| SCHEMBL6062346 | 0.75 | CTSS (0.34) | CTSSALDH1A1CTDSP1 | |
| SCHEMBL6063234 | 0.75 | KDM4E (0.37) | CTSSALDH1A1 | |
| SCHEMBL7043390 | 0.74 | SCN9A (0.31) | EPHX2 | |
| SCHEMBL7042185 | 0.73 | ATM (0.39) | EPHX2CYP2C9ALDH1A1PTPN1 | |
| SCHEMBL6062448 | 0.69 | FAAH (0.38) | EPHX2CYP2C9RBP4CTSSALDH1A1 | |
| SCHEMBL6464516 | 0.69 | CTSS (0.50) | CYP2C9CTSSCTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | EPHX2 696/4885CYP2C9 1807/4885RBP4 3433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.